Logo image of BCAB

BIOATLA INC (BCAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCAB - US09077B1044 - Common Stock

0.3602 USD
-0.04 (-10.08%)
Last: 1/9/2026, 7:16:33 PM
0.368 USD
+0.01 (+2.17%)
After Hours: 1/9/2026, 7:16:33 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BCAB. BCAB was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of BCAB have multiple concerns. BCAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCAB had negative earnings in the past year.
In the past year BCAB has reported a negative cash flow from operations.
BCAB had negative earnings in each of the past 5 years.
In the past 5 years BCAB always reported negative operating cash flow.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

BCAB has a worse Return On Assets (-438.62%) than 93.58% of its industry peers.
Industry RankSector Rank
ROA -438.62%
ROE N/A
ROIC N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

BCAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCAB has more shares outstanding
BCAB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BCAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -62.13, we must say that BCAB is in the distress zone and has some risk of bankruptcy.
BCAB's Altman-Z score of -62.13 is on the low side compared to the rest of the industry. BCAB is outperformed by 91.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -62.13
ROIC/WACCN/A
WACC8.83%
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BCAB has a Current Ratio of 0.54. This is a bad value and indicates that BCAB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.54, BCAB is doing worse than 89.62% of the companies in the same industry.
A Quick Ratio of 0.54 indicates that BCAB may have some problems paying its short term obligations.
BCAB has a Quick ratio of 0.54. This is amonst the worse of the industry: BCAB underperforms 89.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.35% over the past year.
The Revenue has been growing by 16.17% on average over the past years. This is quite good.
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%-100%

3.2 Future

BCAB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.71% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y23.5%
EPS Next 2Y16.12%
EPS Next 3Y5.41%
EPS Next 5Y5.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2M 4M 6M 8M 10M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.12%
EPS Next 3Y5.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOATLA INC

NASDAQ:BCAB (1/9/2026, 7:16:33 PM)

After market: 0.368 +0.01 (+2.17%)

0.3602

-0.04 (-10.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners28.64%
Inst Owner Change0.01%
Ins Owners10.17%
Ins Owner Change-0.64%
Market Cap21.18M
Revenue(TTM)11.00M
Net Income(TTM)-69.78M
Analysts85.71
Price Target10.2 (2731.76%)
Short Float %8.3%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.91%
Min EPS beat(2)7.04%
Max EPS beat(2)10.77%
EPS beat(4)4
Avg EPS beat(4)16.72%
Min EPS beat(4)7.04%
Max EPS beat(4)26.47%
EPS beat(8)8
Avg EPS beat(8)19.05%
EPS beat(12)11
Avg EPS beat(12)14.38%
EPS beat(16)14
Avg EPS beat(16)11.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.88%
EPS NY rev (1m)0%
EPS NY rev (3m)9.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.19
BVpS-0.53
TBVpS-0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -438.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -62.13
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)10.18%
Cap/Depr(5y)31.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.73%
EPS Next Y23.5%
EPS Next 2Y16.12%
EPS Next 3Y5.41%
EPS Next 5Y5.71%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y42.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.02%
OCF growth 3YN/A
OCF growth 5YN/A

BIOATLA INC / BCAB FAQ

What is the ChartMill fundamental rating of BIOATLA INC (BCAB) stock?

ChartMill assigns a fundamental rating of 0 / 10 to BCAB.


What is the valuation status for BCAB stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOATLA INC (BCAB). This can be considered as Overvalued.


Can you provide the profitability details for BIOATLA INC?

BIOATLA INC (BCAB) has a profitability rating of 0 / 10.